BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rodriguez-castro KI, Simioni P, Burra P, Senzolo M. Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis. Liver Int 2012;32:1465-76. [DOI: 10.1111/j.1478-3231.2012.02839.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Cerini F, Garcia-pagán JC. Thromboprophylaxis with heparin in hospitalized patients with cirrhosis: friend or foe. Liver Int 2014;34:971-3. [DOI: 10.1111/liv.12453] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
2 De Maria C, Galante A, Fasoli A, De Gottardi A. When and how to use direct oral anticoagulants in patients with advanced chronic liver disease? Curr Opin Pharmacol 2021;60:111-6. [PMID: 34403992 DOI: 10.1016/j.coph.2021.07.006] [Reference Citation Analysis]
3 Pasta L, Pasta F. PAI-1 4G-4G and MTHFR 677TT in non-hepatitis C virus/hepatitis B virus-related liver cirrhosis. World J Hepatol 2015; 7(29): 2920-2926 [PMID: 26689658 DOI: 10.4254/wjh.v7.i29.2920] [Reference Citation Analysis]
4 Lee S, Uhm J, Kim J, Pak H, Lee M, Joung B. The safety and efficacy of vitamin K antagonist in patients with atrial fibrillation and liver cirrhosis. International Journal of Cardiology 2015;180:185-91. [DOI: 10.1016/j.ijcard.2014.11.183] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
5 李陈婕, 羊志辉, 施小六, 卢放根, 刘德良. 肝硬化门静脉血栓形成危险因素的Meta分析. 世界华人消化杂志 2017; 25(3): 241-251 [DOI: 10.11569/wcjd.v25.i3.241] [Reference Citation Analysis]
6 Cui SB, Shu RH, Yan SP, Wu H, Chen Y, Wang L, Zhu Q. Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B. Eur J Gastroenterol Hepatol. 2015;27:914-919. [PMID: 25856686 DOI: 10.1097/meg.0000000000000351] [Cited by in Crossref: 50] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
7 Lisman T, Porte RJ. Pathogenesis, prevention, and management of bleeding and thrombosis in patients with liver diseases. Res Pract Thromb Haemost 2017;1:150-61. [PMID: 30046685 DOI: 10.1002/rth2.12028] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 14.5] [Reference Citation Analysis]
8 Blasi A. Coagulopathy in liver disease: Lack of an assessment tool. World J Gastroenterol 2015; 21(35): 10062-10071 [PMID: 26401071 DOI: 10.3748/wjg.v21.i35.10062] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
9 Dai J, Qi X, Li H, Guo X. Role of D-dimer in the Development of Portal Vein Thrombosis in Liver Cirrhosis: A Meta-analysis. Saudi J Gastroenterol. 2015;21:165-174. [PMID: 26021776 DOI: 10.4103/1319-3767.157567] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
10 Qi X, De Stefano V, Li H, Dai J, Guo X, Fan D. Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis of observational studies. Eur J Intern Med. 2015;26:23-29. [PMID: 25566699 DOI: 10.1016/j.ejim.2014.12.002] [Cited by in Crossref: 84] [Cited by in F6Publishing: 67] [Article Influence: 14.0] [Reference Citation Analysis]
11 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol. 2016;64:179-202. [PMID: 26516032 DOI: 10.1016/j.jhep.2015.07.040] [Cited by in Crossref: 291] [Cited by in F6Publishing: 202] [Article Influence: 48.5] [Reference Citation Analysis]
12 Lee KH, Joung B, Lee S, Hwang YM, Park J, Baek YS, Park YM, Park J, Park HC, Park HW, Lee YS, Choi KJ. 2018 KHRS Expert Consensus Recommendation for Oral Anticoagulants Choice and Appropriate Doses: Specific Situation and High Risk Patients. Korean J Med 2018;93:110-32. [DOI: 10.3904/kjm.2018.93.2.110] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
13 Bezinover D, Dirkmann D, Findlay J, Guta C, Hartmann M, Nicolau-raducu R, Mukhtar AM, Moguilevitch M, Pivalizza E, Rosenfeld D, Saner F, Wray C, Wagener G, West J. Perioperative Coagulation Management in Liver Transplant Recipients. Transplantation 2018;102:578-92. [DOI: 10.1097/tp.0000000000002092] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 10.3] [Reference Citation Analysis]
14 Andriulli A, Tripodi A, Angeli P, Senzolo M, Primignani M, Giannini EG, Riggio O, Colli A, Prati D, Sacerdoti D, Merkel C, Basili S, Ferro D, Villa E, Di Minno G, Caraceni P, Marzioni M, Mannucci PM, Violi F, Piscaglia F, Calvaruso V, De Pietri L, Falcone M, Feltracco P, Grandone E, La Mura V, Licata A, Lucidi C, Maimone S, Marietta M, Morisco F, Napoleone L, Piano S, Raparelli V, Rebulla P, Ribero D, Sartori MT, Scalera A, Schepis F, Siciliano M, Baroni GS, Tufano A, Vitale A, Zuin M. Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. Digestive and Liver Disease 2016;48:455-67. [DOI: 10.1016/j.dld.2016.02.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
15 Whitsett M, Wilcox J, Yang A, Zhao L, Rinella M, VanWagner LB. Atrial fibrillation is highly prevalent yet undertreated in patients with biopsy-proven nonalcoholic steatohepatitis. Liver Int 2019;39:933-40. [PMID: 30536602 DOI: 10.1111/liv.14018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
16 Congly SE, Lee SS. Portal vein thrombosis: should anticoagulation be used? Curr Gastroenterol Rep. 2013;15:306. [PMID: 23314804 DOI: 10.1007/s11894-012-0306-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
17 Husic-Selimovic A, Gornjakovic S, Schuchmann M, Vukobrat-Bijedic Z. Evaluation of portal vein thrombosis in liver graft ten years after liver transplantation due to budd-Chiari syndrome using Doppler ultrasound. Acta Inform Med 2012;20:194-5. [PMID: 23322979 DOI: 10.5455/aim.2012.20.194-195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
18 Rodriguez-Castro KI. Anticoagulation for portal vein thrombosis in cirrhosis - Response to Naeshiro and collaborators. Hepatol Res. 2015;Epub ahead of print. [PMID: 25594445 DOI: 10.1111/hepr.12491] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Martín-llahí M, Albillos A, Bañares R, Berzigotti A, García-criado MÁ, Genescà J, Hernández-gea V, Llop-herrera E, Masnou-ridaura H, Mateo J, Navascués CA, Puente Á, Romero-gutiérrez M, Simón-talero M, Téllez L, Turon F, Villanueva C, Zarrabeitia R, García-pagán JC. Enfermedades vasculares del hígado. Guías Clínicas de la Sociedad Catalana de Digestología y de la Asociación Española para el Estudio del Hígado. Gastroenterología y Hepatología 2017;40:538-80. [DOI: 10.1016/j.gastrohep.2017.03.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
20 Görtzen J, Hunka LM, Vonnahme M, Praktiknjo M, Kaifie A, Fimmers R, Jansen C, Heine A, Lehmann J, Goethert JR, Gattermann N, Goekkurt E, Platzbecker U, Brossart P, Strassburg CP, Brummendorf TH, Koschmieder S, Wolf D, Trebicka J. γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm. Medicine (Baltimore) 2016;95:e3355. [PMID: 27196445 DOI: 10.1097/MD.0000000000003355] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Aiyappan SK, Ranga U, Veeraiyan S. Unusual cause for abdominal pain in cirrhosis : thrombosed intrahepatic portal vein aneurysms. J Clin Diagn Res 2014;8:MD01-2. [PMID: 25478385 DOI: 10.7860/JCDR/2014/9536.4940] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Ribic C, Crowther M. Thrombosis and anticoagulation in the setting of renal or liver disease. Hematology Am Soc Hematol Educ Program 2016;2016:188-95. [PMID: 27913479 DOI: 10.1182/asheducation-2016.1.188] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
23 Sucker C, Litmathe J. Orale Antikoagulation mit Vitamin K-Antagonisten – ein Update. Wien Med Wochenschr 2018;168:121-32. [DOI: 10.1007/s10354-017-0577-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
24 Nakayama S, Murashima N. Acute Portal Vein Thrombosis Treated with Recombinant Human Soluble Thrombomodulin Combined with Antithrombin III. Case Rep Med 2020;2020:8268016. [PMID: 32328109 DOI: 10.1155/2020/8268016] [Reference Citation Analysis]
25 Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I, Shibuya A, Seike M, Nagoshi S, Segawa M, Tsubouchi H, Moriwaki H, Kato A, Hashimoto E, Michitaka K, Murawaki T, Sugano K, Watanabe M, Shimosegawa T. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol 2016;51:629-50. [PMID: 27246107 DOI: 10.1007/s00535-016-1216-y] [Cited by in Crossref: 181] [Cited by in F6Publishing: 163] [Article Influence: 36.2] [Reference Citation Analysis]
26 Abdel-Razik A, Mousa N, Elhelaly R, Tawfik A. De-novo portal vein thrombosis in liver cirrhosis: risk factors and correlation with the Model for End-stage Liver Disease scoring system. Eur J Gastroenterol Hepatol 2015;27:585-92. [PMID: 25769098 DOI: 10.1097/MEG.0000000000000325] [Cited by in Crossref: 45] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
27 Cho J, Choi SM, Yu SJ, Park YS, Lee CH, Lee SM, Yim JJ, Yoo CG, Kim YW, Han SK, Lee J. Bleeding complications in critically ill patients with liver cirrhosis. Korean J Intern Med 2016;31:288-95. [PMID: 26805633 DOI: 10.3904/kjim.2014.152] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
28 Kirschner M, do Ó Hartmann N, Parmentier S, Hart C, Henze L, Bisping G, Griesshammer M, Langer F, Pabinger-Fasching I, Matzdorff A, Riess H, Koschmieder S. Primary Thromboprophylaxis in Patients with Malignancies: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO), the Society of Thrombosis and Hemostasis Research (GTH), and the Austrian Society of Hematology and Oncology (ÖGHO). Cancers (Basel) 2021;13:2905. [PMID: 34200741 DOI: 10.3390/cancers13122905] [Reference Citation Analysis]
29 Rout G, Shalimar, Gunjan D, Mahapatra SJ, Kedia S, Garg PK, Nayak B. Thromboelastography-guided Blood Product Transfusion in Cirrhosis Patients With Variceal Bleeding: A Randomized Controlled Trial. J Clin Gastroenterol. 2020;54:255-262. [PMID: 31008867 DOI: 10.1097/mcg.0000000000001214] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 28.0] [Reference Citation Analysis]
30 Aggarwal A, Puri K, Liangpunsakul S. Deep vein thrombosis and pulmonary embolism in cirrhotic patients: Systematic review. World J Gastroenterol 2014; 20(19): 5737-5745 [PMID: 24914335 DOI: 10.3748/wjg.v20.i19.5737] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
31 周佳, 杨晋辉. 肝硬化非肿瘤性门静脉血栓的治疗进展. 世界华人消化杂志 2015; 23(5): 735-740 [DOI: 10.11569/wcjd.v23.i5.735] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Riess H, Habbel P, Jühling A, Sinn M, Pelzer U. Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers - Review. World J Gastrointest Oncol 2016; 8(3): 258-270 [PMID: 26989461 DOI: 10.4251/wjgo.v8.i3.258] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
33 Intagliata NM, Henry ZH, Shah N, Lisman T, Caldwell SH, Northup PG. Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding. Liver Int 2014;34:26-32. [DOI: 10.1111/liv.12211] [Cited by in Crossref: 62] [Cited by in F6Publishing: 47] [Article Influence: 7.8] [Reference Citation Analysis]
34 Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis. Gastroenterology 2019; 156: 1582-1599. e1. [PMID: 30771355 DOI: 10.1053/j.gastro.2019.01.265] [Cited by in Crossref: 79] [Cited by in F6Publishing: 65] [Article Influence: 39.5] [Reference Citation Analysis]
35 Ha NB, Regal RE. Anticoagulation in Patients With Cirrhosis: Caught Between a Rock-Liver and a Hard Place. Ann Pharmacother. 2016;50:402-409. [PMID: 26861989 DOI: 10.1177/1060028016631760] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
36 Riva N, Ageno W, Poli D, Testa S, Rupoli S, Santoro R, Lerede T, Piana A, Carpenedo M, Nicolini A, Ferrini PM, Tosetto A; the Italian Federation of Anticoagulation Clinics (FCSA). Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study. J Thromb Haemost 2015;13:1019-27. [DOI: 10.1111/jth.12930] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
37 Lee HF, Chan YH, Chang SH, Tu HT, Chen SW, Yeh YH, Wu LS, Kuo CF, Kuo CT, See LC. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation. J Am Heart Assoc 2019;8:e011112. [PMID: 30834802 DOI: 10.1161/JAHA.118.011112] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 22.0] [Reference Citation Analysis]
38 Rodríguez-Castro KI, Antonello A, Ferrarese A. Spontaneous bleeding or thrombosis in cirrhosis: What should be feared the most? World J Hepatol 2015; 7(14): 1818-1827 [PMID: 26207163 DOI: 10.4254/wjh.v7.i14.1818] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
39 Zhou JB, Luo BY, Liu CW, Zhu F. Effects of early antiplatelet therapy after splenectomy with gastro-oesophageal devascularization. ANZ J Surg 2018;88:E725-9. [PMID: 29396900 DOI: 10.1111/ans.14395] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]